Imaging Autotaxin In Vivo with 18 F-Labeled Positron Emission Tomography Ligands
Deng, X., Salgado-Polo, F., Shao, T., Xiao, Z., Van, R., Chen, J., Rong, J., Haider, A., Shao, Y., Josephson, L., Perrakis, A., Liang, S.H.(2021) J Med Chem 64: 15053-15068
- PubMed: 34662125
- DOI: https://doi.org/10.1021/acs.jmedchem.1c00913
- Primary Citation of Related Structures:
7P0K - PubMed Abstract:
Autotaxin (ATX) is a secreted phosphodiesterase that has been implicated in a remarkably wide array of pathologies, especially in fibrosis and cancer. While ATX inhibitors have entered the clinical arena, a validated probe for positron emission tomography (PET) is currently lacking. With the aim to develop a suitable ATX-targeted PET radioligand, we have synthesized a focused library of fluorinated imidazo[1,2- a ]pyridine derivatives, determined their inhibition constants, and confirmed their binding mode by crystallographic analysis. Based on their promising in vitro properties, compounds 9c , 9f , 9h , and 9j were radiofluorinated. Also, a deuterated analog of [ 18 F] 9j , designated as [ 18 F]ATX-1905 ([ 18 F] 20 ), was designed and proved to be highly stable against in vivo radiodefluorination compared with [ 18 F] 9c , [ 18 F] 9f , [ 18 F] 9h , and [ 18 F] 9j . These results along with in vitro and in vivo studies toward ATX in a mouse model of LPS-induced liver injury suggest that [ 18 F]ATX-1905 is a suitable PET probe for the non-invasive quantification of ATX.
Organizational Affiliation:
Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.